Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 1
2016 1
2017 1
2018 1
2019 2
2020 3
2021 4
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Results by year
Filters applied: . Clear all
Page 1
Kinetic analysis and optimisation of 18F-rhPSMA-7.3 PET imaging of prostate cancer.
Malaspina S, Oikonen V, Kuisma A, Ettala O, Mattila K, Boström PJ, Minn H, Kalliokoski K, Postema EJ, Miller MP, Scheinin M. Malaspina S, et al. Among authors: kuisma a. Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3723-3731. doi: 10.1007/s00259-021-05346-8. Epub 2021 Apr 12. Eur J Nucl Med Mol Imaging. 2021. PMID: 33846844 Free PMC article.
Prediction of prostate cancer aggressiveness using 18F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI.
Movahedi P, Merisaari H, Perez IM, Taimen P, Kemppainen J, Kuisma A, Eskola O, Teuho J, Saunavaara J, Pesola M, Kähkönen E, Ettala O, Liimatainen T, Pahikkala T, Boström P, Aronen H, Minn H, Jambor I. Movahedi P, et al. Among authors: kuisma a. Sci Rep. 2020 Jun 10;10(1):9407. doi: 10.1038/s41598-020-66255-8. Sci Rep. 2020. PMID: 32523075 Free PMC article. Clinical Trial.
Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S, Kemppainen J, Kauppila E, Auren J, Merisaari H, Saunavaara J, Noponen T, Minn H, Aronen HJ, Seppänen M. Jambor I, et al. Among authors: kuisma a. Acta Oncol. 2016;55(1):59-67. doi: 10.3109/0284186X.2015.1027411. Epub 2015 Apr 2. Acta Oncol. 2016. PMID: 25833330
Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer.
Saarinen I, Jambor I, Kim M, Kuisma A, Kemppainen J, Merisaari H, Eskola O, Koskenniemi AR, Perez IM, Boström P, Taimen P, Minn H. Saarinen I, et al. Among authors: kuisma a. EJNMMI Res. 2019 May 31;9(1):50. doi: 10.1186/s13550-019-0518-5. EJNMMI Res. 2019. PMID: 31152256 Free PMC article.
In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548.
Kähkönen E, Jambor I, Kemppainen J, Lehtiö K, Grönroos TJ, Kuisma A, Luoto P, Sipilä HJ, Tolvanen T, Alanen K, Silén J, Kallajoki M, Roivainen A, Schäfer N, Schibli R, Dragic M, Johayem A, Valencia R, Borkowski S, Minn H. Kähkönen E, et al. Among authors: kuisma a. Clin Cancer Res. 2013 Oct 1;19(19):5434-43. doi: 10.1158/1078-0432.CCR-12-3490. Epub 2013 Aug 9. Clin Cancer Res. 2013. PMID: 23935037 Free article.
11 results